Grant W. Brown

Grant W. Brown

Auto-generated profile, based on publicly available information

Grant W. Brown

University of Toronto

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 February 2004 in Science
Verified
Journal Article
Closed access
PDF file
ATAmy Hin Yan Tong
Amy Hin Yan Tong
GLGuillaume Lesage
Guillaume Lesage
GBGary Bader
Gary Bader
HDHuiming Ding
Huiming Ding
HXHong Xu
Hong Xu
CBCharles Boone
Charles Boone
A genetic interaction network containing ∼1000 genes and ∼4000 interactions was mapped by crossing mutations in 132 different query genes into a set of ∼4700 viable gene yeast deletion mutants and scoring the double mutant progeny for fitness defects. Network connectivity was predictive of function because interactions often occurred among functionally related genes, and similar patterns of interactions tended to identify components of the same pathway. The genetic network exhibited dense local neighborhoods; therefore, the position of a gene on a partially mapped network is predictive of other genetic interactions. Because digenic interactions are common in yeast, similar networks may underlie the complex genetics associated with inherited phenotypes in other organisms.

21 February 2007 in Nature
Verified
Journal Article
Closed access
PDF file
SCSean R. Collins
Sean R. Collins
KMKyle Miller
Kyle Miller
NMNancy L. Maas
Nancy L. Maas
ARAssen Roguev
Assen Roguev
JFJeffrey Fillingham
Jeffrey Fillingham
NKNevan J. Krogan
Nevan J. Krogan

7 December 2003 in Nature Biotechnology
Verified
Journal Article
Closed access
PDF file
APAinslie B Parsons
Ainslie B Parsons
RBRenée L Brost
Renée L Brost
HDHuiming Ding
Huiming Ding
ZLZhijian Li
Zhijian Li
CZChaoying Zhang
Chaoying Zhang
CBCharles Boone
Charles Boone

29 July 2012 in Nature Cell Biology
Verified
Journal Article
Open access
PDF file
JTJohnny M. Tkach
Johnny M. Tkach
AYAskar Yimit
Askar Yimit
ALAnna Y. Lee
Anna Y. Lee
MRMichael Riffle
Michael Riffle
MCMichael Costanzo
Michael Costanzo
GBGrant W. Brown
Grant W. Brown
Relocalization of proteins is a hallmark of the DNA damage response. We use high-throughput microscopic screening of the yeast GFP fusion collection to develop a systems-level view of protein reorganization following drug-induced DNA replication stress. Changes in protein localization and abundance reveal drug-specific patterns of functional enrichments. Classification of proteins by subcellular destination enables the identification of pathways that respond to replication stress. We analysed pairwise combinations of GFP fusions and gene deletion mutants to define and order two previously unknown DNA damage responses. In the first, Cmr1 forms subnuclear foci that are regulated by the histone deacetylase Hos2 and are distinct from the typical Rad52 repair foci. In a second example, we find that the checkpoint kinases Mec1/Tel1 and the translation regulator Asc1 regulate P-body formation. This method identifies response pathways that were not detected in genetic and protein interaction screens, and can be readily applied to any form of chemical or genetic stress to reveal cellular response pathways.

17 February 2017 in Nature Communications
Verified
Journal Article
Open access
PDF file
HXHong Xu
Hong Xu
MAMarco Di Antonio
Marco Di Antonio
SMSteven McKinney
Steven McKinney
VMVeena Mathew
Veena Mathew
BHBrandon Ho
Brandon Ho
SASamuel Aparicio
Samuel Aparicio
G-quadruplex DNAs form four-stranded helical structures and are proposed to play key roles in different cellular processes. Targeting G-quadruplex DNAs for cancer treatment is a very promising prospect. Here, we show that CX-5461 is a G-quadruplex stabilizer, with specific toxicity against BRCA deficiencies in cancer cells and polyclonal patient-derived xenograft models, including tumours resistant to PARP inhibition. Exposure to CX-5461, and its related drug CX-3543, blocks replication forks and induces ssDNA gaps or breaks. The BRCA and NHEJ pathways are required for the repair of CX-5461 and CX-3543-induced DNA damage and failure to do so leads to lethality. These data strengthen the concept of G4 targeting as a therapeutic approach, specifically for targeting HR and NHEJ deficient cancers and other tumours deficient for DNA damage repair. CX-5461 is now in advanced phase I clinical trial for patients with BRCA1/2 deficient tumours (Canadian trial, NCT02719977, opened May 2016).

1 February 2018 in Cell Systems
Verified
Journal Article
Closed access
BHBrandon Ho
Brandon Ho
ABAnastasia Baryshnikova
Anastasia Baryshnikova
GBGrant W. Brown
Grant W. Brown